Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.
Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.
复制标题
DOI：
10.1111/aos.13436
复制
发表时间：
2018-03
影响因子：
3.4
通讯作者：
ODISSEY European Consensus Group Members
中科院分区：
文献类型：
--
作者：
Baudouin C;Irkeç M;Messmer EM;Benítez-Del-Castillo JM;Bonini S;Figueiredo FC;Geerling G;Labetoulle M;Lemp M;Rolando M;Van Setten G;Aragona P;ODISSEY European Consensus Group Members
干眼症（DED）是一种常见的多因素眼部疾病，对视力和生活质量有重大影响。现在公认慢性DED的病理生理学可包括涉及先天性和适应性免疫应答的炎症循环。最近，体外/体内模型已被用于在分子/细胞水平上更好地了解DED相关的炎症过程，尽管它们不能真正再现人类DED的复杂和慢性特征。在临床DED研究中，先进的技术，如印模细胞学，结膜活检，体内共聚焦显微镜和多重泪液分析，使DED患者的炎症评估得到改善。这得到了泪液和印迹细胞学样本中可靠炎症标志物（包括基质金属蛋白酶-9、人白细胞抗原-DR或细胞间粘附分子-1）鉴定的支持。目前的治疗策略之一集中在打破使眼表疾病永久存在的炎症循环，并且临床前/临床研究已经导致有前景的抗炎化合物的开发。例如，已经在美国批准的环孢霉素最近在欧洲被批准用于治疗与严重角膜炎相关的DED。此外，其他药物，如皮质类固醇，强力霉素和必需脂肪酸，通过其抗炎特性，显示出令人鼓舞的结果。我们现在对DED中涉及的炎症过程有了更清楚的了解，并且有希望在不久的将来将仍然出现的临床前/临床发现转化为新的高效治疗方法。
Dry eye disease (DED) is a common, multifactorial ocular condition with major impact on vision and quality of life. It is now well recognized that the pathophysiology of chronic DED can include a cycle of inflammation involving both innate and adaptive immune responses. Recently, in vitro/in vivo models have been used to obtain a better understanding of DED‐related inflammatory processes at molecular/cellular levels although they do not truly reproduce the complex and chronic hallmarks of human DED. In clinical DED research, advanced techniques such as impression cytology, conjunctival biopsy, in vivo confocal microscopy and multiplex tear analyses have allowed an improved assessment of inflammation in DED patients. This was supported by the identification of reliable inflammatory markers including matrix metalloproteinase‐9, human leucocyte antigen‐DR or intercellular adhesion molecule‐1 in tears and impression cytology samples. One of the current therapeutic strategies focuses on breaking the inflammatory cycle perpetuating the ocular surface disease, and preclinical/clinical research has led to the development of promising anti‐inflammatory compounds. For instance, cyclosporine, already approved in the United States, has recently been authorized in Europe to treat DED associated with severe keratitis. In addition, other agents such as corticosteroids, doxycycline and essential fatty acids, through their anti‐inflammatory properties, show encouraging results. We now have a clearer understanding of the inflammatory processes involved in DED, and there is hope that the still emerging preclinical/clinical findings will be translated into new and highly effective therapies for patients in the near future.
登录
查看更多内容
影响因子：
4.4
作者：
Chotikavanich S;de Paiva CS;Li de Q;Chen JJ;Bian F;Farley WJ;Pflugfelder SC
通讯作者：
Pflugfelder SC
影响因子：
4.4
作者：
Barabino, S;Dana, MR
通讯作者：
Dana, MR
影响因子：
3.4
作者：
De Paiva, Cintia S.;Corrales, Rosa M.;Pfiugfelder, Stephen C.
通讯作者：
Pfiugfelder, Stephen C.
影响因子：
1.7
作者：
Aragona, Pasquale;Spinella, Rosaria;Puzzolo, Domenico
通讯作者：
Puzzolo, Domenico
影响因子：
2.8
作者：
Corrales, Rosa M.;Villarreal, Arturo;Pflugfelder, Stephen C.
通讯作者：
Pflugfelder, Stephen C.